At Fifteen Months Post-Launch, AbbVie’s Qulipta Outperforms Pfizer’s Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights
![](https://www.spherixglobalinsights.com/wp-content/uploads/2022/06/1600799882684.png)
Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on par. Exton, PA., March 16, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch of AbbVie’s Qulipta for the preventive treatment […]
The IgA Nephropathy Landscape Has Experienced Rapid Changes Over Past Two Years with Increased Use of SGLT2 Inhibitors and Tarpeyo (Calliditas); More Change on The Way with Filspari (Travere) Launch, According to Spherix Global Insights
Content Area
Early Launch Metrics for TG Therapeutics’ Briumvi in RMS Trail Those of Novartis’ In-Class Competitor Kesimpta, According to Spherix Global Insights
![](https://www.spherixglobalinsights.com/wp-content/uploads/2022/05/Emma-McFadden.png)
Content Area
Despite Market Access Hurdles and Limited Familiarity Hampering Initial Uptake, Neurologists Project Robust Future Use of Relyvrio for the Treatment of ALS, According to Spherix Global Insights
![](https://www.spherixglobalinsights.com/wp-content/uploads/2022/05/Emma-McFadden.png)
Recent research suggests Relyvrio will benefit from the limited number of therapies approved to slow decline in ALS Exton, PA., March 9, 2023 – With the FDA approval of Amylyx’s Relyvrio (AMX0035; sodium phenylbutyrate and taurursodiol) for amyotrophic lateral sclerosis (ALS) in September 2022, patients gained access to only the third novel molecule approved for […]
US Neurologists Cautiously Optimistic About Potential Approval of Pfizer’s Zavegepant for the Acute Treatment of Migraine, According to Spherix Global Insights
![](https://www.spherixglobalinsights.com/wp-content/uploads/2022/06/1600799882684.png)
Recently released positive phase 3 data for Pfizer’s zavegepant likely to fuel already noted perceptions among prescribers that the brand will have a high responder rate. Exton, PA., February 28, 2023 – On February 16, The Lancet Neurology published the Phase 3 results of Pfizer’s zavegepant for the acute treatment of migraine. The CGRP receptor […]
Apellis Ushers in a New Era of Geographic Atrophy Treatment with First Ever Approval, According to Spherix Global Insights
![](https://www.spherixglobalinsights.com/wp-content/uploads/2023/01/Chrystal-Ferguson-web-1-e1680194362114.jpg)
Spherix Global Insights surveyed 85 US ophthalmologists, revealing awareness of Apellis’s newly approved GA therapy, Syfovre is high, as are intentions to trial the agent Exton, PA., February 28, 2023 – Apellis Pharmaceuticals recently made history with the approval of Syfovre (pegcetacoplan) for the treatment for Geographic Atrophy (GA). GA is an advanced form of […]
Spherix Global Insights Continues Coverage of Biogen & Coherus Biosciences’ Ranibizumab Biosimilars, Tracking Uptake and Perceptions of the First Commercially Available Biosimilars to Genentech’s Lucentis
![](https://www.spherixglobalinsights.com/wp-content/uploads/2023/01/Chrystal-Ferguson-web-1-e1680194362114.jpg)
According to a survey of ophthalmologists, in the first six months of biosimilar availability, aided awareness and familiarity are marginal while willingness to prescribe is low. Exton, PA., February 24, 2023 – Last summer, the introduction of biosimilar agents into ophthalmologists’ armamentarium was a big event in the United States medical community. Despite the availability […]
One Year Post-Launch of Argenx’s Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights
![](https://www.spherixglobalinsights.com/wp-content/uploads/2022/05/Emma-McFadden.png)
Despite early satisfaction with Vyvgart, half of surveyed neurologists & neuromuscular specialists report uncertainty regarding re-dosing after the first treatment cycle Exton, PA., February 24, 2023 – Argenx’s launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic approved for generalized myasthenia gravis (gMG) and […]
Retina Specialist: Why are ophthalmologists a definite maybe about biosimilars? Survey provides answers
February 14, 2023 Even with the launch of the first two anti-VEGF biosimilars last year, retina specialists seem somewhat ambivalent about using these copy-cat versions of tried and true treatments, a new report based on a survey of ophthalmologists has found. The report, titled “Special Topix: Ophthalmology Biosimilars Today and Tomorrow,” is based on a […]
Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
![](https://www.spherixglobalinsights.com/wp-content/uploads/2022/05/Emma-McFadden.png)
U.S. neurologists increasingly favor Novartis’ MS portfolio, particularly Kesimpta Exton, PA., February 17, 2023 – According to Biogen’s earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third year in a row. The company attributed the 2022 decline to generic erosion, pricing pressures, and a shift […]